Surveillance versus adjuvant radiotherapy for patients with high‐risk stage I seminoma

The optimal treatment strategy for patients with clinical stage I (CS‐1) seminoma is controversial. The objective of the current study was to evaluate the outcomes for patients considered to be at high risk of disease recurrence with a tumor size ≥6 cm. Patients were treated with either adjuvant radiotherapy (RT) or followed with surveillance.

[1]  R. Wahlqvist,et al.  Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  A. Horwich,et al.  Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.

[3]  R. Huddart,et al.  2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma , 2015 .

[4]  Ramneek Gupta,et al.  Germ Cell Cancer and Multiple Relapses: Toxicity and Survival. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Crabb,et al.  Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Hancock,et al.  Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology , 2015 .

[7]  O. Ståhl,et al.  Surveillance vs. adjuvant therapy of clinical stage I testicular tumors – a review and the SWENOTECA experience , 2015, Andrology.

[8]  P. Hall,et al.  Increased stomach cancer risk following radiotherapy for testicular cancer , 2014, British Journal of Cancer.

[9]  P. Warde,et al.  Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance , 2014, Cancer medicine.

[10]  T. Powles,et al.  Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Hancock,et al.  Testicular Cancer, Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  I. Christensen,et al.  A nationwide cohort study of stage I seminoma patients followed on a surveillance program. , 2014, European urology.

[13]  D. Dearnaley,et al.  Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma , 2013, British Journal of Cancer.

[14]  P. Warde,et al.  Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy , 2013, BJU international.

[15]  S. Fosså,et al.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  C. Lawton.  Management of Seminomatous Testicular Cancer: A Binational Prospective Population-Based Study From the Swedish Norwegian Testicular Cancer Study Group , 2012 .

[17]  B. Davis,et al.  Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  X. G. Del Muro,et al.  Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Helweg-larsen.  The Danish Register of Causes of Death , 2011, Scandinavian journal of public health.

[20]  B. Bjerregaard,et al.  The Danish Pathology Register , 2011, Scandinavian journal of public health.

[21]  Elsebeth Lynge,et al.  The Danish National Patient Register , 2011, Scandinavian journal of public health.

[22]  G. Rustin,et al.  Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  R. Huddart,et al.  Canadian consensus guidelines for the management of testicular germ cell cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[24]  T. Powles,et al.  The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Louwman,et al.  Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Horwich,et al.  Guidelines on testicular cancer. , 2005, European urology.

[27]  O. Klepp,et al.  European Association of Urology GUIDELINES ON TESTICULAR CANCER , 2004 .

[28]  H. Storm,et al.  The Danish Cancer Registry--history, content, quality and use. , 1997, Danish medical bulletin.

[29]  G. Mead,et al.  The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[30]  M. Ro̸rth,et al.  Surveillance following orchidectomy for stage I seminoma of the testis. , 1993, European journal of cancer.